Related Articles
Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors
Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report
Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy‑naïve patients with advanced or metastatic non‑small‑cell lung cancer: Long‑term follow‑up results
TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3